Skip to content

Lilly’s Jardiance Fast Track’d in U.S. to improve outcomes following heart attack

September 15, 2020

he FDA designates Eli Lilly’s (NYSE:LLY) type 2 diabetes med Jardiance (empagliflozin) for Fast Track review to prevent hospitalization for heart failure and reduce the risk of mortality in patients, with and without diabetes, who have had an acute myocardial infarction.

A Phase 3 clinical trial, EMPACT-MI, is in process.

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

The company is developing and commercializing the product, along with others, with Boehringer Ingelheim under a 2011 agreement.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: